Back to Course

EXPLAINED: State Regulation of Medication Abortion

Dr. Ushma Upadhyay, of the University of California San Francisco, explains the most up-to-date research on the state regulation of medication abortion.

For more information, watch the extended lecture version and download the video companion materials.

The following links provided the research used in this video:

Chong E, Frye LJ, Castle J, Dean G, Kuehl L, Winikoff B. A prospective, non-randomized study of home use of mifepristone for medical abortion in the U.S. 2015;92(3):215-219.
Clinical Practice Handbook for Safe Abortion. World Health Organization; 2014.
Greene MF, Drazen JM. A New Label for Mifepristone. N Eng J Med. 2016;374(23):2281-2282.
Grossman D, Grindlay K, Buchacker T, Lane K, Blanchard K. Effectiveness and acceptability of medical abortion provided through telemedicine. Obstet Gynecol. 2011;118(2 Pt 1):296-303.
Grossman DA, Grindlay K, Buchacker T, Potter JE, Schmertmann CP. Changes in service delivery patterns after introduction of telemedicine provision of medical abortion in Iowa. Am J Public Health. 2013;103(1):73-78.
Mitka M. Some men who take Viagra die–why? 2000;283(5):590, 593.
Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947-954.
Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Eng J Med. 1998;338(18):1241-1247.
Upadhyay UD, Desai S, Zlidar V, et al. Incidence of emergency department visits and complications after abortion. Obstet Gynecol. 2015;125(1):175-183.
Upadhyay UD, Johns NE, Combellick SL, Kohn JE, Keder LM, Roberts SC. Comparison of Outcomes before and after Ohio’s Law Mandating Use of the FDA-Approved Protocol for Medication Abortion: A Retrospective Cohort Study. PLoS Med. 2016;13(8):e1002110.
Winikoff B, Westhoff C. Fifteen years: looking back and looking forward. 2015;92(3):177-178.